Abstract
Apoptosis, the cells intrinsic death program, is a key regulator of tissue homeostasis. Thus, any imbalance between cell death and proliferation may favor tumor formation. Moreover, killing of cancer cells by cytotoxic therapies currently used in clinical oncology such as chemotherapy or γ-irradiation is primarily mediated by triggering apoptosis as well as other forms of cell death in cancer cells. Accordingly, defects in apoptosis pathways may lead to cancer resistance. Understanding the molecular pathways that regulate apoptosis in different types of malignancies and how resistant cancer cells successfully evade to undergo apoptosis may provide novel opportunities for cancer drug development. Thus, apoptosis pathways may be exploited for cancer treatment by directly triggering cell death in tumor cells, e.g. via ligation of death receptors, or by enhancing the efficacy of conventional cancer therapies, e.g. by blockade of anti-apoptotic programs. In this review we will focus on the potential exploitation of the death receptor pathway, in particular TRAIL, for cancer therapy. Also, we will discuss signal transduction therapy targeting Inhibitor of Apoptosis Proteins (IAPs).
Current Signal Transduction Therapy
Title: Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers
Volume: 1 Issue: 2
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: Apoptosis, cancer, TRAIL, IAP
Abstract: Apoptosis, the cells intrinsic death program, is a key regulator of tissue homeostasis. Thus, any imbalance between cell death and proliferation may favor tumor formation. Moreover, killing of cancer cells by cytotoxic therapies currently used in clinical oncology such as chemotherapy or γ-irradiation is primarily mediated by triggering apoptosis as well as other forms of cell death in cancer cells. Accordingly, defects in apoptosis pathways may lead to cancer resistance. Understanding the molecular pathways that regulate apoptosis in different types of malignancies and how resistant cancer cells successfully evade to undergo apoptosis may provide novel opportunities for cancer drug development. Thus, apoptosis pathways may be exploited for cancer treatment by directly triggering cell death in tumor cells, e.g. via ligation of death receptors, or by enhancing the efficacy of conventional cancer therapies, e.g. by blockade of anti-apoptotic programs. In this review we will focus on the potential exploitation of the death receptor pathway, in particular TRAIL, for cancer therapy. Also, we will discuss signal transduction therapy targeting Inhibitor of Apoptosis Proteins (IAPs).
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Signal Transduction Therapy Targeting Apoptosis Pathways in Cancers, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012075
DOI https://dx.doi.org/10.2174/157436206777012075 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Editorial [Hot Topic: TGF-β As Target in Oncology (Guest Editor: Karl-Hermann Schlingensiepen)]
Current Pharmaceutical Biotechnology Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews 5-HT5 Receptors
Current Drug Targets - CNS & Neurological Disorders Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Novel Cell Nucleus Directed Fluorescent Tetraazacyclododecane-Tetraacetic Acid Compounds
Medicinal Chemistry Editorial [Hot topic: Current Formulations and Techniques of Drug/gene Delivery for Targeted Therapy and Tissue Engineering (Executive Editors: Chi-Hwa Wang and Sudhir H. Ranganath)]
Current Pharmaceutical Design Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry